Eli Lilly (LLY)
$112.80
0.73 (0.64%)
LLY Stock Quote Delayed 15 Minutes
Previous Close
$112.80
Market Cap
122.44B
PE Ratio
105.42
EPS
1.07
Volume (Avg. Vol.)
1.77M
Day's Range
112.22 - 114.21
52-Week Range
101.36 - 132.13
Dividend & Yield
2.25 (2.00%)
LLY Stock Predictions, Articles, and Eli Lilly News
3 Big Stock Charts for Thursday: Cisco Systems, Eli Lilly, and Colgate-Palmolive
These big stock charts highlight three value plays left behind in the market's shift away from growth stocks.
3 Big Stock Charts for Wednesday: General Mills, Eli Lilly and Hartford Financial Services
Stock charts of LLY, HIG and GIS are moving into the midpoint of the week on the verge of major moves.
4 Drug Stocks Getting Smashed
Drug stocks are falling on fears of President Trump's next move on drug prices. Here's a look at the charts.
3 Big Stock Charts for Tuesday: Eli Lilly, SYSCO and Interpublic Group
The stock charts of Eli Lilly, SYSCO and Interpublic Group are knocking on the door of some trade-worthy moves.
3 Big Stock Charts for Thursday: H & R Block, Boeing and Eli Lilly
The stock charts of LLY, BA and HRB are moving into pivotal positions as the trading week starts to wind down.
3 Big Stock Charts for Wednesday: Juniper Networks, Eli Lilly and Hormel Foods
The stock charts of HRL, JNPR and LLY stock are moving into the midpoint of the week on the cusp of something trade-worthy.
Credit Suisse Absolutely Is Right to Double Down on Pfizer Stock
Buy Pfizer stock on this current round of weakness. The underpinnings are bullish for 2020 and beyond.
Is AstraZeneca Stock Worth Buying Before Earnings?
AZN stock is great to own, but you should choose your entry points carefully, as AstraZeneca has some short-term risks ahead.
The Numbers Say Eli Lilly Stock Has Still More Upside For Investors
The bull thesis in Eli Lilly stock has strong qualitative and quantitative support, making it pretty hard to refute or ignore.
The Case Against Pfizer Stock and the Rest of the Industry
A recent article in the investment media asked if Pfizer stock was a better buy than Eli Lilly stock. Here’s why I wouldn’t buy either.
Eli Lilly’s Latest Move Proves the American Healthcare System Is Broken
In 2018, Humalog generated $3.0 billion for Eli Lilly, 5% higher than a year earlier. Assuming Humalog’s gross margin is 73.8% (I’m using the company’s overall gross margin; it’s likely higher), Eli Lilly had $2.2 billion in gross profits from this single drug. Except for Trulicity, the company’s bestselling diabetes drug, Humalog is the company’s second-largest revenue and profit generator.
3 Big Stock Charts for Tuesday: D. R. Horton, PPL and CF Industries
The stock charts of PPL, CF and DHI are all on the precipice of major moves, though each one has one more hurdle to clear.
3 Big Stock Charts for Friday: Eli Lilly, Centene and LKQ Corporation
The stock charts of LLY, LKQ and CNC deserve a closer look through a technical trading lens as the trading week winds down.
Thursday’s Vital Data: Eli Lilly, Twitter and Freeport-McMoRan
Options trading was abuzz in Eli Lilly, Twitter and Freeport-McMoRan on Wednesday. Here are the metrics and levels that matter here.
Eli Lilly News: LLY Stock Falls on Sarcoma Study Failure
In the latest Eli Lilly news, LLY stock fell more than 2% as the company's late-stage trial of a sarcoma study failed to meet its goals.
5 Must-See Stock Charts for Tuesday, Including Roku
Roku soared, while the S&P 500, Twilio, Eli Lilly and Nvidia all perked up as well. Here are a few must-see stock charts for Tuesday.
Navellier Ratings
Powered by Portfolio GraderTotal Grade
C
10 Stocks Set for Monster Growth
He found Apple at $4… Oracle at $6… Amazon at $40… Now legendary growth investor Louis Navellier is giving away his latest Research Report — for FREE!
Download your FREE COPY!
